Charles Schwab Investment Management Inc. Boosts Stake in Fresenius Medical Care AG (NYSE:FMS)

Charles Schwab Investment Management Inc. lifted its position in Fresenius Medical Care AG (NYSE:FMS) by 11.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,161 shares of the company’s stock after purchasing an additional 2,233 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Fresenius Medical Care were worth $472,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in FMS. Signaturefd LLC boosted its stake in shares of Fresenius Medical Care by 8.4% during the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after buying an additional 672 shares during the period. Ritholtz Wealth Management grew its stake in shares of Fresenius Medical Care by 2.5% in the 2nd quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock valued at $704,000 after purchasing an additional 895 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Fresenius Medical Care by 6.7% in the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock valued at $345,000 after purchasing an additional 1,128 shares during the period. Caprock Group LLC purchased a new stake in shares of Fresenius Medical Care during the second quarter worth approximately $208,000. Finally, Koss Olinger Consulting LLC acquired a new stake in shares of Fresenius Medical Care during the second quarter worth $286,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Price Performance

Shares of NYSE FMS opened at $22.48 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $24.31. The firm has a market capitalization of $13.19 billion, a P/E ratio of 18.58, a PEG ratio of 0.96 and a beta of 0.94. The company’s fifty day moving average is $21.76 and its two-hundred day moving average is $20.53.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. StockNews.com started coverage on shares of Fresenius Medical Care in a research note on Thursday, November 28th. They issued a “strong-buy” rating on the stock. Truist Financial boosted their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Berenberg Bank started coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective for the company. Finally, Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.